BiotechTube

IV Loop Diuretics

Pre-clinicalRecruiting
1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heart Failure (for Example, Fluid Overload)

Conditions

Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload

Trial Timeline

Jun 28, 2022 → Dec 31, 2026

NCT ID
NCT05318105

About IV Loop Diuretics

IV Loop Diuretics is a pre-clinical stage product being developed by Nuwellis for Heart Failure (for Example, Fluid Overload). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05318105. Target conditions include Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure (for Example, Fluid Overload) were approved

Approved (20) Terminated (2) Active (0)
✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
✅ConivaptanAstellas PharmaApproved
✅RegadenosonAstellas PharmaApproved
✅Regadenoson + GadoliniumAstellas PharmaApproved
✅regadenosonAstellas PharmaApproved
✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical
3
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05318105Pre-clinicalRecruiting

Competing Products

20 competing products in Heart Failure (for Example, Fluid Overload)

See all competitors
ProductCompanyStageHype Score
mRNA-0184ModernaPhase 1
0
IV diureticNuwellisPre-clinical
16
Stepped pharmacologic careNuwellisPhase 3
30
IV Loop Diuretics (LD)NuwellisPre-clinical
8
TRV120027 + Normal SalineTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
TRV120027 + PlaceboTrevenaPhase 1/2
22
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
INXN-4001PrecigenPhase 1
23
LY3461767 + PlaceboEli LillyPhase 1
29
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
43
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
32
OlmesartanDaiichi SankyoPhase 3
40
Carperitide + PlaceboDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
22
RegadenosonAstellas PharmaPhase 1
29
Advagraf + PrografAstellas PharmaPhase 2
35
FK506EAstellas PharmaPhase 3
40